Notice this is plural "undisclosed therapeutic ind
Post# of 30028
The news release is all about retinal repair which narrows down the list of orphans a bit. One can speculate why Amarantus has kept this hush-hush where RP has been know for a long-time. If this leads to treatment of AMD, that could be huge.
San Francisco, CA, Geneva, SWITZERLAND and Novato, CA – August 11, 2014 - Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, announced it has entered into a Research Collaboration with the Buck Institute for Research on Aging for the development of Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) in undisclosed therapeutic indications . MANF is a targeted therapeutic which addresses the underlying programmed cell death (apoptosis) associated with a wide range of devastating human disorders including orphan indications such as Retinitis Pigmentosa.
http://www.buckinstitute.org/buck-news/amaran...laboration